Article in Press
Back to the articles list |
Back to browse issues page
Department of Neurosurgery, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
Abstract: (159 Views)
Cancer-associated thrombosis (CAT) represents a significant challenge in patients with brain tumors, with venous thromboembolism (VTE) affecting up to 30% of those with high-grade gliomas and 20% of those with brain metastases or primary CNS lymphoma. The primary clinical dilemma lies in balancing the prevention of thrombosis with the heightened risk of intracranial hemorrhage (ICH). The heightened risk of VTE is driven by tumor-induced hypercoagulability and the effects of cancer treatments. The present literature review evaluated evidence from PubMed/MEDLINE and Web of Science. Clinical studies, mechanistic research, and guidelines (ASCO/NCCN) were prioritized, while case reports and non-English studies were excluded. Diagnosing VTE in brain tumor patients is complicated by overlapping symptoms with tumor progression and treatment side effects, as well as limitations in imaging and biomarker tests. Effective management of CAT requires balancing the prevention of thrombosis with the minimization of ICH risks. Low-molecular-weight heparin (LMWH) remains the preferred anticoagulant, although direct oral anticoagulants (DOACs) are emerging as potential alternatives. While prophylactic anticoagulation is recommended in high-risk perioperative settings, its routine use in other contexts remains controversial due to bleeding risks. The VTE significantly impacts survival and quality of life, increasing mortality and symptom burden. Future efforts should focus on improving risk stratification, exploring novel anticoagulants, and personalizing treatment plans. Additionally, the limitations of existing studies, such as the lack of robust data on DOACs in this population, must be addressed. Multidisciplinary collaboration and ongoing research are crucial for advancing the prevention and treatment of CAT in patients with brain tumors.
Type of Study: Review |
Subject:
Neurosurgery
Received: 2025/03/15 | Accepted: 2025/05/27 | ePublished ahead of print: 2025/06/10
Received: 2025/03/15 | Accepted: 2025/05/27 | ePublished ahead of print: 2025/06/10
References
1. Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. Semin Thromb Hemost. 2014;40(3):325-31. [DOI:10.1055/s-0034-1370791]
2. Unruh D, Schwarze SR, Khoury L, et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in brain tumors. Nat Cancer. 2023;4(5):678-92.
3. Muster V, Gary T. Incidence, therapy, and bleeding risk-cancer-associated thrombosis in patients with glioblastoma. Cancers. 2020;12(6):1354. [DOI:10.3390/cancers12061354]
4. Khorana AA, Mackman N, Falanga A, Pabinger I, Noble S, Ageno W, et al. Cancer-associated venous thromboembolism. Nat Rev Dis Primers. 2022;8(1):11. [DOI:10.1038/s41572-022-00336-y]
5. Carney BJ, Wang TF, Al-Samkari H, et al. Management of cancer-associated thrombosis in patients with primary brain tumors: A systematic review and meta-analysis. J Thromb Haemost. 2024;22(1):112-25.
6. Diaz M, Jo J. Venous thrombotic events and anticoagulation in brain tumor patients. Curr Oncol Rep. 2022;24(4):493-500. [DOI:10.1007/s11912-021-01178-9]
7. Diaz M, Schiff D. Vascular complications in patients with brain tumors. Curr Opin Oncol. 2022;34(6):698-704. [DOI:10.1097/CCO.0000000000000875]
8. Greenberg SM, Ziai WC, Cordonnier C, et al. Anticoagulant selection for cancer-associated thrombosis in neuro-oncology: An international Delphi consensus. Neuro-Oncol Pract. 2023;10(4):389-401.
9. Magnus N, D'Asti E, Garnier D, Meehan B, Rak J. Brain neoplasms and coagulation. Semin Thromb Hemost. 2013;39(8):881-95. [DOI:10.1055/s-0033-1357483]
10. Campello E, Ilich A, Simioni P, Key NS. The role of microparticles in cancer-associated thrombosis: A focus on brain tumors. Blood Rev. 2025;54:100931.
11. Bierwagen M, Wierciński M, Góralczyk K, Góralczyk B, Janczarek A, Kulwas A, et al. Tissue factor-dependent coagulation activation in intracranial neoplasms: a comparative study. Blood Coagul Fibrinolysis. 2022;33(8):438-48. [DOI:10.1097/MBC.0000000000001164]
12. Riedl J, Preusser M, Nazari PM, Posch F, Panzer S, Marosi C, et al. Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. Blood. 2017;129(13):1831-9. [DOI:10.1182/blood-2016-06-720714]
13. Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro-Oncol. 2012;14 (Suppl 4):iv73-80. [DOI:10.1093/neuonc/nos197]
14. Jo J, Diaz M, Horbinski C, Mackman N, Bagley S, Broekman M, et al. Epidemiology, biology, and management of venous thromboembolism in gliomas: an interdisciplinary review. Neuro-Oncol. 2023;25(8):1381-94. [DOI:10.1093/neuonc/noad059]
15. Leader A, Wilcox JA, Zwicker JI. How I treat acute venous thromboembolism in patients with brain tumors. Blood. 2024;144(17):1781-90. [DOI:10.1182/blood.2023023450]
16. Helfer H, Skaff Y, Happe F, Djennaoui S, Chidiac J, Poénou G, et al. Diagnostic approach for venous thromboembolism in cancer patients. Cancers. 2023;15(11):3031. [DOI:10.3390/cancers15113031]
17. Winther-Larsen A, Sandfeld-Paulsen B, Hvas AM. New insights in coagulation and fibrinolysis in patients with primary brain cancer: a systematic review. Semin Thromb Hemost. 2022;48(3):323-37. [DOI:10.1055/s-0041-1733961]
18. Swan D, Seiffge DJ, Thachil J. A review of anticoagulation in patients with central nervous system malignancy: between a rock and a hard place. J Neurol. 2021;268(7):2390-2401. [DOI:10.1007/s00415-020-09775-7]
19. Swartz AW, Drappatz J. Safety of direct oral anticoagulants in central nervous system malignancies. Oncologist. 2021;26(5):427-32. [DOI:10.1002/onco.13698]
20. Wilhelmy F, Gaier M, Planitzer U, Kasper J, prasse G, Frydrychowicz C, et al. Venous thromboembolism and intracranial hemorrhage in patients undergoing glioblastoma surgery. Sci Rep. 2023;13(1):21679. [DOI:10.1038/s41598-023-48542-2]
21. Bailey D, Wilding H, Ganesalingam N, Rizk E. Perioperative management of antiplatelet and anticoagulation in brain tumor surgery: a survey of international practices. World Neurosurg. 2024;190:e271-e280. [DOI:10.1016/j.wneu.2024.07.111]
22. Riedl J, Ay C. Venous thromboembolism in brain tumors: risk factors, molecular mechanisms, and clinical challenges. Semin Thromb Hemost. 2019;45(4):334-41. [DOI:10.1055/s-0039-1688493]
23. Iyengar V, Patell R, Zwicker J. Challenges in anticoagulation for patients with brain tumors. Best Pract Res Clin Haematol. 2022;35(1):101350. [DOI:10.1016/j.beha.2022.101350]
24. Sartori MT, Della Puppa A, Ballin A, Campello E, Radu CM, Saggiorato G, et al. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thromb Haemost. 2013;110(2):378-85. [DOI:10.1160/TH12-12-0957]
25. Leader A, Wilcox JA, Zwicker JI. How I treat acute venous thromboembolism in patients with brain tumors. Blood. 2024;144(17):17 81-90. [DOI:10.1182/blood.2023023450]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Attribution-NoneCommercial CC BY-NC
